This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Health care stocks were on the rise Wednesday, aided by rises in Ventana Medical Systems (VMSI) and Pfizer (PFE - Get Report).

On Tuesday, a U.S. District Court in Arizona granted Swiss drug maker Roche a preliminary injunction, preventing Ventana from using anti-takeover provisions to hold off a $3 billion hostile takeover bid. Roche said on Tuesday that it was extending its $75-a-share offer, originally set to expire on Aug. 23, until Sept. 20. Ventana's shares edged up $1.07, or 1.3%, to $83.45.

Pfizer introduced Frank D'Amelio as its new CFO. D'Amelio was most recently a senior executive vice president and chief administrative officer at Alcatel-Lucent. The appointment will be effective mid-September. The company rose 39 cents, or 1.6%, to $24.63.

A much smaller company, Critical Therapeutics (CRTX) also named a new CFO. The biopharmaceutical company said it appointed Tucker Kelly to chief financial officer and senior vice president of finance and corporate development. Kelly's resume includes experience as a life sciences investment banker, a principal with Canaccord Adams, a vice president with Robertson Stephens, and as a corporate and securities attorney.

Critical Therapeutics also filed with regulators on Tuesday to periodically sell up to $40 million in common and preferred stock, debt securities and warrants. The proceeds will be used for general corporate purposes. The company gave up 18 cents, or 7.9%, to $2.09.

Another biopharmaceutical company, Medicure (MCU), was moving in the other direction Wednesday. Medicure said it now anticipates completion of enrollment of its phase IIII Med-Carg II trial in September, two months earlier than planned. The company said it received another recommendation to continue the trial from the independent Data Safety Monitoring Board.

Medicure said on Tuesday that it entered into two agreements that will result in proceeds of about $40 million. The company will issue about 13.04 million shares at $1.15 apiece, with warrants to purchase about 3.69 million additional common shares within the next five years for $1.50 each. It also entered into an agreement with Manchester Securities to securitize revenue from Aggrastat, a treatment for acute coronary syndrome, and possibly revenue from its MC-1 compound for acute cardiovascular events, upon its commercialization.

Medicure's shares were up 2 cents, or 1.7%, to $1.20.

Nuvelo (NUVO) was gaining 16.3% after Brean Murray upgraded the stock to hold, from sell. also rose after reporting news on a drug trial. The company said earlier this week that it re-initiated its Sonoma-3 study on Alfimeprase in patients with catheter occlusion. A previous phase III trial didn't meet effectiveness standards for a single pivotal trial. The new trial is studying a single, higher and more concentrated dose. Shares rose 21 cents, or 12.9%, to $1.84.

Nuvelo is a component of the Nasdaq Biotechnology Index, which was up 4.41, or 0.55%, to 803.95.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $33.63 0.69%
CRTX $0.00 0.00%
AAPL $92.80 -0.88%
FB $117.93 -0.11%
GOOG $699.00 0.47%


Chart of I:DJI
DOW 17,659.93 +8.67 0.05%
S&P 500 2,055.29 +4.17 0.20%
NASDAQ 4,734.0610 +8.4220 0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs